Cohance Lifesciences to hold 8th AGM on Sep 17, 2026; E-voting from Sep 14-16
Cohance Lifesciences Limited will hold its 8th Annual General Meeting on September 17, 2026. The meeting will include the adoption of financial statements for FY26 and consider the reappointment of Director Ms. Shweta Jalan. E-voting will be open from September 14 to September 16, 2026.
The announcement is a procedural notice regarding the AGM and does not involve any immediate material changes to the company's operations, financials, or strategic direction.
The announcement is a routine corporate event (AGM notice) and does not contain any specific financial performance data or strategic decisions that would warrant a positive or negative sentiment.
Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) has announced its 8th Annual General Meeting (AGM) will be held on Thursday, September 17, 2026, at 4:00 p.m. IST. The meeting will be conducted through Video Conference (VC) / Other Audio Visual Means (OAVM). The company has also released its Integrated Annual Report for the financial year 2025-26.
The AGM will include ordinary business, such as the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026. Additionally, Ms. Shweta Jalan will be considered for reappointment as a Director.
Shareholders will have the opportunity to participate in e-voting. The cut-off date for e-voting is Thursday, September 10, 2026. Remote e-voting will commence on Monday, September 14, 2026, at 9:00 a.m. IST, and conclude on Wednesday, September 16, 2026, at 5:00 p.m. IST. The company has provided detailed instructions for attending the AGM via VC/OAVM and for participating in e-voting through its registrar and transfer agent, KFin Technologies Limited.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.